XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
BASIS OF PRESENTATION (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2021
Net loss     $ (4,457,401) $ (1,441,393) $ (18,542,654) $ (13,830,371)      
Net cash used in operations         14,998,919        
Working capital         12,285,310        
Amortization of right-of-use assets     14,918 67,097 23,686 85,696      
Accumulated deficit $ (96,101,634)   (96,101,634)   (91,644,233) (66,232,813)      
Stockholders' equity 32,119,574 $ 43,669,058 32,119,574 43,669,058 36,043,028 39,284,295 $ 34,546,682 $ 44,007,783 $ 4,379,463
Revenue 13,206,717 $ 12,363,429 27,791,190 $ 24,713,206 $ 53,376,874 $ 50,347,652      
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                  
Net cash used in operations     4,622,989            
Working capital 8,593,711   8,593,711            
Amortization of right-of-use assets     1,606,650            
Cash proceed $ 629,426   $ 629,426            
Proceeds from sale of common stock     901,488